Dual GIP/GLP-1 agonists like tirzepatide outperform single GLP-1 drugs for blood sugar control and weight loss, while both incretins offer significant cardiovascular protection.
Dual agonists outperform single GLP-1 drugsTirzepatide, the first dual GIP/GLP-1 agonist, shows superior glycemic control and weight loss compared to selective GLP-1 receptor agonists in clinical trials
What the researchers found
Dual GIP/GLP-1 receptor agonists, led by tirzepatide, provide superior glycemic control and weight loss compared to selective GLP-1 receptor agonists alone, demonstrating synergistic effects between the two incretin pathways. GIP, historically overlooked due to reduced beta-cell responsiveness in type 2 diabetes, has been rehabilitated as a therapeutic target through dual agonism.
The review identifies multiple cardiovascular protective mechanisms of incretin hormones: improved lipid metabolism, blood pressure reduction, enhanced endothelial nitric oxide activity, suppressed macrophage inflammation, decreased foam-cell formation, and atherosclerotic plaque stabilization. Emerging triple agonists and genotype-guided incretin therapy represent the next frontier.
Why it matters
The shift from single GLP-1 agonists to dual and triple incretin agonists represents a paradigm change in metabolic medicine. Understanding how GIP and GLP-1 work together — not just for blood sugar and weight, but also for cardiovascular protection — reshapes how we think about treating the interconnected diseases of diabetes, obesity, and heart disease as a unified metabolic syndrome.
The numbers in context
2 incretin hormones (GIP + GLP-1) · Tirzepatide first-in-class dual agonist · Superior to selective GLP-1RAs · Multiple CV protective mechanisms · Triple agonists in development
How the study worked
Comprehensive narrative review covering incretin biology from basic physiology through clinical therapeutics. Synthesizes evidence on secretion patterns, receptor distributions, pathophysiology in diabetes and obesity, cardiovascular mechanisms, and emerging therapeutic approaches.
Who was studied
Review covering basic science and clinical evidence in people with type 2 diabetes, obesity, and cardiovascular disease
What this study cannot tell us
As a narrative review, this does not provide systematic evidence grading or pooled analysis. Long-term cardiovascular effects of GIP specifically remain unresolved. The review acknowledges that genotype-guided incretin therapy is still speculative.
How to read the evidence
This is a comprehensive narrative review synthesizing evidence from basic science through clinical trials. The underlying evidence for GLP-1 agonists and tirzepatide comes from large randomized controlled trials, providing strong clinical evidence.
When this study was published
Published in 2025, this review captures the very latest developments including tirzepatide's clinical success and emerging triple agonist approaches.
The bigger picture
The incretin field has evolved from simple blood sugar management to comprehensive metabolic and cardiovascular therapy. The recognition that GIP — once dismissed as ineffective in diabetes — contributes powerfully when combined with GLP-1 agonism has opened entirely new therapeutic strategies. This integrated approach to treating metabolic disease may fundamentally change how physicians manage the overlapping conditions of diabetes, obesity, and cardiovascular disease.
Questions still open
- What are the long-term cardiovascular effects of GIP agonism specifically, independent of GLP-1?
- Could genotype-guided selection of incretin therapies improve individual patient outcomes?
- How will triple agonists (targeting GLP-1, GIP, and glucagon receptors) compare to dual agonists in efficacy and safety?
Common questions
What are incretin hormones and what do they do?
Why is tirzepatide considered a breakthrough compared to earlier GLP-1 drugs?
Read the original research
The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.
International journal of molecular sciences, 27(1)
Citation
Yamanouchi, Dai. (2025). The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.. International journal of molecular sciences, 27(1). https://doi.org/10.3390/ijms27010027